A3365 Comparative Effectiveness of Angiotensin II Receptor Blocker Versus Angiotensin Converting Enzyme Inhibitor in Left Ventricular Structure and Function
R. Ma,Y. Zhao,Q. Y. Wang,N. Y. Li,H. T. Meng,J. Yu
DOI: https://doi.org/10.1097/01.hjh.0000548016.48370.be
IF: 4.9
2016-01-01
Journal of Hypertension
Abstract:Objective: Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor 1 antagonists (ARB) both ameliorate fibrosis of myocardium, however, the difference between this two renin angiotensin system antagonists in protection to organ damages remains controversial. The purpose of this study is to find out if irbesartan and benazepril alone and in combination would have different protective effects on left ventricular structure and function. Design and Method: Sixteen weeks old spontaneously hypertensive rats (SHR) (n=8) were treated with irbesartan (Irb), benazepril (Ben), combination of low irbesartan and benazepril (Irb+Ben) and vehicle for 12 weeks. Wistar Kyoto (WKY) rats (n = 8) receive vehicle. Echocardiography was performed for evaluation of left ventricular structure, systolic and diastolic function at 12 weeks. Results: Systolic blood pressure was significantly lower in Irb+Ben rats than in untreated SHR, and demonstrated greater improvement than irbesartan or benazepril alone. IVSd was significantly lower in the Irb+Ben rats, Irb rats and Ben rats than untreated SHR (P = 0.010, P = 0.035, P = 0.028, separately). There was no difference in the LVEDD, LVEF and FS between SHR in each group and WKY. E/A showed no statistical difference between groups. E/E’ decreased in Irb+Ben rats, Irb rats and Ben rats compared with untreated SHR (P = 0.007, P = 0.020, P = 0.039, separately). E’/A’ increased in Irb+Ben rats, Irb rats and Ben rats compared with untreated SHR (P = 0.019, P = 0.032, P = 0.041, separately). Irb+Ben combination resulted in better outcomes of IVSd, E/E’ and E’/A’ than irbesartan or benazepril alone (P < 0.05 for all). Conclusions: The development of hypertension was associated with diastolic dysfunction. Irbesartan, benazepril and dual therapy provide therapeutic benefit in the improvement of left ventricular hypertrophy and diastolic dysfunction. The combination significantly attenuating hypertension and reducing left ventricular hypertrophy than monotherapy could be related to the better antihypertensive effect. There was no evidence of differential effect of irbesartan and benazepril on the outcomes of left ventricular structure and function.